My bookmarksSign up free
Source

Commission Implementing Decision (EU) 2018/133 of 24 January 2018 amending Decision 2008/911/EC shing a list of herbal substances, preparations and combinations thereof for use in traditional herbal medicinal products (notified under document C(2018) 213) (Text with EEA relevance. )

Commission Implementing Decision (EU) 2018/133 of 24 January 2018 amending Decision 2008/911/EC shing a list of herbal substances, preparations and combinations thereof for use in traditional herbal medicinal products (notified under document C(2018) 213) (Text with EEA relevance. )

Implementing Decision (EU) 2018/133 · Decision · 3 articles

Data as of 2026-07-04 · Compiled from an official source version. Later amendments or repeals may not be reflected; the official text prevails. · Read the official text ↗

Article 1

Open ↗

Annexes I and II to Decision 2008/911/EC are amended in accordance with the Annex to this Decision.

Supplementary provisions

ANNEXSupplementary provisions

Open ↗

ANNEX Decision 2008/911/EC is amended as follows: (1) in Annex I, the following substance is inserted after Thymus vulgaris L., Thymus zygis Loefl. ex L., aetheroleum: ‘ Valeriana officinalis L.’; (2) in Annex II, the following is inserted after the COMMUNITY LIST ENTRY on Thymus vulgaris L., Thymus zygis Loefl. ex L., aetheroleum: ‘UNION LIST ENTRY ON VALERIANA OFFICINALIS L. Scientific name of the plant Valeriana officinalis L. Botanical family Valerianaceae Common name in all EU official languages of herbal preparation BG (bălgarski): Валериана, корен CS (čeština): kozlíkový kořen DA (dansk): Baldrianrod DE (Deutsch): Baldrianwurzel EL (elliniká): Ρίζα βαλεριανής EN (English): Valerian root ES (español): Valeriana, raíz de ET (eesti keel): palderjanijuur FI (suomi): rohtovirmajuuri, juuri FR (français): Valériane (racine de) HR (hrvatska): odoljenov korijen HU (magyar): Macskagyökér IT (italiano): Valeriana radice LT (lietuvių kalba): Valerijonų šaknys LV (latviešu valoda): Baldriāna saknes MT (Malti): Għerq tal-Valerjana NL (Nederlands): Valeriaanwortel PL (polski): Korzeń kozłka PT (português): Valeriana, raiz RO (română): rădăcină de valeriană SK (slovenčina): Koreň valeriány SL (slovenščina): korenina zdravilne špajke SV (svenska): Vänderot, rot IS (íslenska): NO (norsk): Valerianarot Herbal preparation(s) (a) Comminuted herbal substance (b) Powdered herbal substance (c) Expressed juice from fresh root (1:0,60-0,85) (d) Dry extract (DER 4-6:1), extraction solvent: water (e) Liquid extract (DER 1:4-6), extraction solvent: water (f) Dry extract (DER 4-7:1), extraction solvent: methanol 45 % (V/V) (g) Dry extract (DER 5,3-6,6:1), extraction solvent: methanol 45 % (m/m) (h) Liquid extract (DER 1:7-9), extraction solvent: sweet wine (i) Liquid extract (DER 1:1), extraction solvent: ethanol 60 % (V/V) (j) Tincture (ratio of herbal substance to extraction solvent 1:8), extraction solvent: ethanol 60 % (V/V) (k) Tincture (ratio of herbal substance to extraction solvent 1:10), extraction solvent: ethanol 56 % (l) Tincture (ratio of herbal substance to extraction solvent 1:5), extraction solvent: ethanol 70 % (V/V) (m) Tincture (ratio of herbal substance to extraction solvent 1:5), extraction solvent: ethanol 60-80 % (V/V) (n) Dry extract (DER 5,5-7,4:1), extraction solvent: ethanol 85 % (m/m) European Pharmacopoeia monograph reference 04:2017:0453 Indications Traditional herbal medicinal product for relief of mild symptoms of mental stress and to aid sleep. The product is a traditional herbal medicinal product for use in the specified indication exclusively based upon long-standing use. Type of tradition European. Specified strength Please see ‘Specified posology’. Specified posology Adolescents, adults and elderly Oral use (a) single dose: 0,3-3 g For relief of mild symptoms of mental stress up to 3 times daily. To aid sleep, a single dose half to one hour before bedtime with an earlier dose during the evening if necessary. Herbal tea: 0,3-3 g of the comminuted herbal substance in 150 ml of boiling water as a herbal infusion (b) single dose: 0,3-2,0 g For relief of mild symptoms of mental stress up to 3 times daily. To aid sleep, a single dose half to one hour before bedtime with an earlier dose during the evening if necessary. (c) single dose: 10 ml For relief of mild symptoms of mental stress up to 3 times daily. To aid sleep, a single dose half to one hour before bedtime with an earlier dose during the evening if necessary. (d) single dose: 420 mg For relief of mild symptoms of mental stress up to 3 times daily. To aid sleep, a single dose half to one hour before bedtime with an earlier dose during the evening if necessary. (e) single dose: 20 ml For relief of mild symptoms of mental stress up to 3 times daily. To aid sleep, a single dose half to one hour before bedtime. (f) single dose: 144-288 mg For relief of mild symptoms of mental stress up to 4 times daily. To aid sleep, a single dose half to one hour before bedtime with an earlier dose during the evening if necessary. (g) single dose: 450 mg For relief of mild symptoms of mental stress up to 3 times daily. To aid sleep, a single dose half to one hour before bedtime with an earlier dose during the evening if necessary. (h) single dose: 10 ml, up to 3 times daily (i) single dose: 0,3-1,0 ml, up to 3 times daily (j) single dose: 4-8 ml, up to 3 times daily (k) single dose: 0,84 ml For relief of mild symptoms of mental stress 3-5 times daily. To aid sleep, a single dose half an hour before bedtime. (l) single dose: 1,5 ml (mental stress), 3 ml (to aid sleep) For relief of mild symptoms of mental stress up to 3 times daily. To aid sleep, a single dose half an hour before bedtime. (m) single dose: 10 ml, up to 3 times daily (n) single dose: 322 mg, up to 3 times daily Use as bath additive single dose: 100 g for a full bath, up to 1 bath daily Route of administration Oral use Use as bath additive. Temperature: 34-37 °C, duration of bath 10-20 minutes. Duration of use or any restrictions on the duration of use If symptoms persist during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted. Any other information necessary for the safe use Contraindications Hypersensitivity to the active substance. Use as bath additive Full baths are contraindicated in cases of open wounds, large skin injuries, acute skin diseases, high fever, severe infections, severe circulatory disturbances and cardiac insufficiency. Special warnings and precautions for use The use in children under 12 years of age has not been established due to lack of adequate data. If the symptoms worsen during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted. For tinctures and extracts containing ethanol, the appropriate labelling for ethanol, taken from the ‘Guideline on excipients in the label and package leaflet of medicinal products for human use’, must be included. Interactions with other medicinal products and other forms of interaction None reported Fertility, pregnancy and lactation Safety during pregnancy and lactation has not been established. In the absence of sufficient data, use during pregnancy and lactation is not recommended. No fertility data available. Effects on ability to drive and use machines May impair ability to drive and use machines. Affected patients should not drive or operate machinery. Undesirable effects Oral use Gastrointestinal symptoms (e.g. nausea, abdominal cramps) may occur after ingestion of valerian root preparations. The frequency is not known. If other adverse reactions not mentioned above occur, a doctor or a qualified health care practitioner should be consulted. Use as bath additive None known If adverse reactions occur, a doctor or a qualified health care practitioner should be consulted. Overdose Oral use Valerian root at a dose of approximately 20 g caused symptoms, such as fatigue, abdominal cramp, chest tightness, light-headedness, hand tremor and mydriasis, which disappeared within 24 hours. If symptoms arise, treatment should be supportive. Use as bath additive No case of overdose has been reported. Pharmaceutical particulars [If necessary] Not applicable Pharmacological effects or efficacy plausible on the basis of long-standing use and experience [If necessary for the safe use of the product] Not applicable.’

Other acts of the same type
Commission Implementing Decision (EU) 2025/2334 of 19 November 2025 excluding from European Union financing certain expenditure incurred by certain Member States under the European Agricultural Guarantee Fund (EAGF) and under the European Agricultural Fund for Rural Development (EAFRD) (notified under document C(2025) 7762)Commission Implementing Decision (EU) 2025/2343 of 19 November 2025 on refusing protection in the Union of the Appellation of Origin ВОЛОГОДСКОЕ КРУЖЕВО (VOLOGODSKOE KRUZHEVO) registered in the International Register of Appellations of Origin and Geographical Indications of the Geneva Act (notified under document C(2025)7686)Commission Implementing Decision (EU) 2025/2366 of 19 November 2025 amending the Annex to Implementing Decision (EU) 2023/2447 concerning emergency measures in relation to outbreaks of highly pathogenic avian influenza in certain Member States (notified under document C(2025) 7999)Commission Implementing Decision (EU) 2025/2361 of 18 November 2025 amending the Annex to Implementing Decision (EU) 2025/2256 concerning emergency measures in relation to outbreaks of Newcastle disease in Poland (notified under document C(2025) 7865)Decision (EU) 2025/2419 of the European Central Bank of 18 November 2025 on the approval of the volume of coin issuance in 2026 (ECB/2025/37)Decision (EU) 2025/2420 of the European Central Bank of 18 November 2025 amending Decision (EU) 2024/3127 on the approval of the volume of coin issuance in 2025 (ECB/2024/38) (ECB/2025/38)Political and Security Committee Decision (CFSP) 2025/2451 of 18 November 2025 on the reconfirmation of the authorisation of the European Union military operation in the Mediterranean (EUNAVFOR MED IRINI) (EUNAVFOR MED IRINI/5/2025)Council Decision of 17 November 2025 appointing four representatives of Member States as members of the Management Board of the European Food Safety AuthorityCouncil Decision of 17 November 2025 adopting the Council’s position on draft amending budget No 3 of the European Union for the financial year 2025Commission Implementing Decision (EU) 2025/2310 of 17 November 2025 amending Implementing Decision (EU) 2021/781 by deleting the reference CO2 emissions (notified under document C(2025)7595)Commission Implementing Decision (EU) 2025/2321 of 17 November 2025 amending Decisions 2007/305/EC, 2007/306/EC and 2007/307/EC as regards the tolerance period for traces of Ms1xRf1 (ACS-BNØØ4-7xACS-BNØØ1-4) hybrid oilseed rape, Ms1xRf2 (ACS-BNØØ4-7xACS-BNØØ2-5) hybrid oilseed rape and Topas 19/2 (ACS-BNØØ7-1) oilseed rape, as well as for their derived products (notified under document C(2025) 7640)Council Decision (EU) 2025/2426 of 17 November 2025 appointing an alternate member, proposed by the Federal Republic of Germany, of the Committee of the Regions

Source: EUR-Lex (Publications Office of the EU), © European Union, reuse permitted under Commission Decision 2011/833/EU.

Contents

What to look at next